Cargando…
Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
BACKGROUND: For safe and efficacious treatment of hereditary angioedema, C1 esterase inhibitor (C1-INH) concentrates should have high purity and high amounts of functional protein. As no pharmacopoeia requirements exist for C1-INH concentrate lot release, biochemical characteristics as declared by t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285325/ https://www.ncbi.nlm.nih.gov/pubmed/24805006 http://dx.doi.org/10.1111/trf.12678 |
_version_ | 1782351570203049984 |
---|---|
author | Feussner, Annette Kalina, Uwe Hofmann, Peter Machnig, Thomas Henkel, Georg |
author_facet | Feussner, Annette Kalina, Uwe Hofmann, Peter Machnig, Thomas Henkel, Georg |
author_sort | Feussner, Annette |
collection | PubMed |
description | BACKGROUND: For safe and efficacious treatment of hereditary angioedema, C1 esterase inhibitor (C1-INH) concentrates should have high purity and high amounts of functional protein. As no pharmacopoeia requirements exist for C1-INH concentrate lot release, biochemical characteristics as declared by the manufacturers may not be compared directly. This study compared the characteristics and purity profiles of four commercially available C1-INH concentrates. STUDY DESIGN AND METHODS: The analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates. C1-INH antigen concentration was determined by nephelometry, total protein (specific activity) with a Bradford assay, purity by size-exclusion chromatography and gel electrophoresis, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was performed. RESULTS: Functionality (inversely proportional to antigen-to-activity ratio) was lowest for Ruconest (1.67), followed by Cetor (1.42), Berinert (1.24), and Cinryze (1.22). Specific activity (U/mg) and purity (%) were highest in Ruconest (12.13; 98.6) and Berinert (11.57; 97.0), followed by Cinryze (10.41; 89.5) and Cetor (9.01; 88.6). Main protein bands were found for all plasma-derived products at approximately 105 kDa, and for Ruconest, at approximately 98 kDa. Additional bands in the plasma-derived products were α1-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert). CONCLUSION: Ruconest has a very high purity profile but is not identical to the human C1-INH protein. Of the plasma-derived products, Berinert has the highest purity profile. The impact of the nontherapeutic proteins identified has not yet been evaluated. For harmonization of the analysis for drug release, we recommend the establishment of regulatory requirements for purity determination and the implementation of threshold levels in C1-INH concentrates. |
format | Online Article Text |
id | pubmed-4285325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42853252015-01-26 Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema Feussner, Annette Kalina, Uwe Hofmann, Peter Machnig, Thomas Henkel, Georg Transfusion Blood Components BACKGROUND: For safe and efficacious treatment of hereditary angioedema, C1 esterase inhibitor (C1-INH) concentrates should have high purity and high amounts of functional protein. As no pharmacopoeia requirements exist for C1-INH concentrate lot release, biochemical characteristics as declared by the manufacturers may not be compared directly. This study compared the characteristics and purity profiles of four commercially available C1-INH concentrates. STUDY DESIGN AND METHODS: The analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates. C1-INH antigen concentration was determined by nephelometry, total protein (specific activity) with a Bradford assay, purity by size-exclusion chromatography and gel electrophoresis, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was performed. RESULTS: Functionality (inversely proportional to antigen-to-activity ratio) was lowest for Ruconest (1.67), followed by Cetor (1.42), Berinert (1.24), and Cinryze (1.22). Specific activity (U/mg) and purity (%) were highest in Ruconest (12.13; 98.6) and Berinert (11.57; 97.0), followed by Cinryze (10.41; 89.5) and Cetor (9.01; 88.6). Main protein bands were found for all plasma-derived products at approximately 105 kDa, and for Ruconest, at approximately 98 kDa. Additional bands in the plasma-derived products were α1-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert). CONCLUSION: Ruconest has a very high purity profile but is not identical to the human C1-INH protein. Of the plasma-derived products, Berinert has the highest purity profile. The impact of the nontherapeutic proteins identified has not yet been evaluated. For harmonization of the analysis for drug release, we recommend the establishment of regulatory requirements for purity determination and the implementation of threshold levels in C1-INH concentrates. BlackWell Publishing Ltd 2014-10 2014-05-08 /pmc/articles/PMC4285325/ /pubmed/24805006 http://dx.doi.org/10.1111/trf.12678 Text en © 2014 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Blood Components Feussner, Annette Kalina, Uwe Hofmann, Peter Machnig, Thomas Henkel, Georg Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema |
title | Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema |
title_full | Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema |
title_fullStr | Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema |
title_full_unstemmed | Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema |
title_short | Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema |
title_sort | biochemical comparison of four commercially available c1 esterase inhibitor concentrates for treatment of hereditary angioedema |
topic | Blood Components |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285325/ https://www.ncbi.nlm.nih.gov/pubmed/24805006 http://dx.doi.org/10.1111/trf.12678 |
work_keys_str_mv | AT feussnerannette biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema AT kalinauwe biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema AT hofmannpeter biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema AT machnigthomas biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema AT henkelgeorg biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema |